Ernexa Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERNA research report →
About the company
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases.
- CEO
- Sanjeev Luther
- IPO
- 1991
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $1.97M
- P/E
- -0.20
- P/S
- 0.00
- P/B
- 0.72
- EV/EBITDA
- 0.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -263.68%
- ROIC
- -138.67%
- Revenue
- $0 · -100.00%
- Net Income
- $-14,084,000 · 68.38%
- EPS
- $-56.00 · -42.68%
- Op Income
- $-9,319,000
- FCF YoY
- 56.47%
- 52W High
- $71.50
- 52W Low
- $3.18
- 50D MA
- $7.65
- 200D MA
- $19.68
- Beta
- 2.47
- Avg Volume
- 1.65M
Get TickerSpark's AI analysis on ERNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 9, 25 | Cherington Charles | buy | 21,241,163 |
| Sep 24, 24 | Cherington Charles | buy | 1,562,988 |
| Sep 24, 24 | Cherington Charles | buy | 5,420,823 |
| Sep 24, 24 | Cherington Charles | buy | 1,237,762 |
| Sep 24, 24 | Cherington Charles | buy | 4,768,783 |
| Sep 24, 24 | Cherington Charles | buy | 261,756 |
Our ERNA coverage
Recent articles, reports, and earnings notes.
No research on ERNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERNA report →Similar companies
Peers in the same neighborhood.